Effects of rituximab on resistant SLE disease including lung involvement

Lupus

Volumn 18, Issue 1, 2009, Pages 67-73

  Reynolds, J A ^a   Toescu, V ^a,b   Yee, C S ^a,b   Prabu, A ^a,b   Situnayake, D ^a   Gordon, C ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

B cells; Lung disease; Rituximab; SLE

Indexed keywords

ANTIRHEUMATIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; LUNG DISEASE; LUNG FUNCTION TEST; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 62749091699     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308094653     Document Type: Article

References (21)

1. D'Cruz, DP. Systemic lupus erythematosus. BMJ 2006; 332: 890-894.
2. Bernatsky, S, Boivin, JF, Joseph, L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2250-2257.
3. Youniou, P, Lydyard, PM, Mageed, RA. B cells underpin lupus immunopathology. Lupus 2002; 11: 1-3.
4. Looney, RJ, Anolik, J, Sanz, I. B lymphocytes in systemic lupus erythematosus: lessons from targeting B cells. Lupus 2004; 13: 381-390.
5. Tedder, TF, Engel, P. CD20: a regulator of cell cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-454.
6. Silverman, GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005; 52: 371-377.
7. Leandro, MJ, Cambridge, G, Edwards, JC, Ehrenstein, MR, Isenberg, DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545.
8. Tokunaga, M, Saito, K, Kawabata, D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475.
9. Tan, EM, Cohen, AS, Fries, JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
10. Cohen, Y, Solal-Celigny, P, Polliack, A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment for relapsed disease, retreatment and maintenance. Haematologica 2003; 88: 811-823.
11. Hay, EM, Bacon, PA, Gordon, C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-458.
12. Gordon, C, Sutcliffe, N, Skan, J, Stoll, T, Isenberg, DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003; 42: 1372-1379.
13. British Thoracic Society and Association of Respiratory Technicians and Physiologists. Guidelines for the measurement of respiratory function. Respir Med 1994; 88: 165-194.
14. Isenberg, DA, Rahman, A, Allen, E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 902-906.
15. Yee, CS, Farewell, V, Isenberg, DA, et al. Revised british isles lupus assessment group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006; 54: 3300-3305.
16. Roodhans, F, Lauwerys, BR, Houssiau Roodhans, F, Lauwerys, BR, Houssiau, FA. Rituximab failure in a patient with severe refractory SLE despite adequate peripheral blood B cell depletion. Ann Rheum Dis 2005; 64(Suppl. 3): 236 [Abstract].
17. Cambridge, G, Leandro, MJ, Teodorescu, M, et al. B cell depletion in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612-3622.
18. Jonsdottir, T, Gunnarsson, I, Risselada, AP, Klareskog, L, Van Vollenhoven, RF. Rituximab plus cyclophosphamide in severe SLE. Ann Rheum Dis 2006; 65(Suppl. 2): 200 [Abstract].
19. Looney, RJ, Anolik, JH, Campbell, D, et al. B Cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II Dose-Escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
20. Saadeh, CK, Ramos, LG, McGee, M, Browm, B, Malacara, JM, Gaylor, MC. Rituxin in extrarenal lupus. Ann Rheum Dis 2005; 64 (Suppl 3): 236 [Abstract].
21. Hersh, ALB, Efthimiou, P. Rituximab in lupus pneumonitis: breathe easier. J Allergy Clin Immunol 2007; 119: S260 [Abstract].